Cellebrite DI Ltd. (NASDAQ:CLBT) Receives Average Rating of “Buy” from Brokerages

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have been given an average recommendation of “Buy” by the eight analysts that are covering the firm, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have covered the stock in the last year is $20.29.

A number of equities research analysts recently commented on CLBT shares. JPMorgan Chase & Co. increased their price target on Cellebrite DI from $21.00 to $22.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Bank of America raised their price target on shares of Cellebrite DI from $13.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Craig Hallum upped their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Needham & Company LLC lifted their target price on shares of Cellebrite DI from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, TD Cowen upped their target price on Cellebrite DI from $20.00 to $23.00 and gave the company a “buy” rating in a report on Monday, September 23rd.

Hedge Funds Weigh In On Cellebrite DI

Several institutional investors and hedge funds have recently bought and sold shares of the company. Quarry LP purchased a new position in shares of Cellebrite DI during the 3rd quarter valued at $27,000. Point72 Asia Singapore Pte. Ltd. lifted its holdings in Cellebrite DI by 59.6% during the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock valued at $33,000 after purchasing an additional 1,017 shares during the last quarter. Advisors Asset Management Inc. boosted its position in Cellebrite DI by 130.5% during the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock worth $52,000 after purchasing an additional 1,742 shares during the period. Pathway Financial Advisers LLC lifted its stake in shares of Cellebrite DI by 1,583.8% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock valued at $74,000 after buying an additional 4,118 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado purchased a new position in Cellebrite DI in the 2nd quarter valued at approximately $71,000. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Stock Performance

Shares of CLBT stock opened at $19.72 on Monday. The firm has a fifty day simple moving average of $17.97 and a two-hundred day simple moving average of $14.85. Cellebrite DI has a 12 month low of $7.91 and a 12 month high of $21.00.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Wednesday, November 6th. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The company had revenue of $106.90 million for the quarter, compared to analyst estimates of $102.06 million. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The firm’s revenue was up 27.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.09 EPS. As a group, analysts predict that Cellebrite DI will post 0.32 earnings per share for the current year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.